Severe fingolimod rebound syndrome after switching to cladribine treatment

被引：11

作者：

Coss-Rovirosa, Fernanda ^{[1
]}

Salado-Burbano, Jorge ^{[1
]}

Casallas-Vanegas, Adriana ^{[2
]}

Elizabeth Caire-Herrera, Laura ^{[3
]}

Gomez-Figueroa, Enrique ^{[1
,2
]}

Flores-Rivera, Jose ^{[1
,2
]}

机构：

[1] Amer British Cowdray Med Ctr, Mexico City, DF, Mexico

[2] Inst Nacl Neurol & Neurocirug, Mexico City, DF, Mexico

[3] Hosp Psiquiatr Infanta Juan N Navarro, Mexico City, DF, Mexico

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 40卷

关键词：

Fingolimod; Rebound; Cladribine; Multiple sclerosis; MULTIPLE-SCLEROSIS; DISEASE REACTIVATION;

D O I：

10.1016/j.msard.2020.101938

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We present the clinical and imaging characteristics of a patient whom presented with rebound syndrome after switching from fingolimod to cladribine treatment due to hematologic toxicity. Previous imaging studies had shown a non-aggressive phenotype of the disease, however multiple active tumefactive lesions became evident after beginning treatment with cladribine. The patient responded well to plasmapheresis.

引用

页数：3

共 50 条

[31] Clinical activity after fingolimod cessation: disease reactivation or rebound?
Frau, J.
Sormani, M. P.
Signori, A.
Realmuto, S.
Baroncini, D.
Annovazzi, P.
Signoriello, E.
Maniscalco, G. T.
La Gioia, S.
Cordioli, C.
Frigeni, B.
Rasia, S.
Fenu, G.
Grasso, R.
Sartori, A.
Lanzillo, R.
Cocco, E.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 911 - 912
[32] Rebound activity after fingolimod cessation: A case - control study
Barboza, Andres
Gaitan, Maria Ines
Alonso, Ricardo
Ysrraelit, Maria Celica
Luetic, Geraldine
Liwacki, Susana
Patrucco, Liliana
Halfon, Mario Javier
Burgos, Marcos
Mainella, Carolina
Pierdabuena, Raul
Recchia, Luciano
Steinberg, Judith
Tkachuk, Veronica Analia
Zanga, Gisela
Carra, Adriana
Chertcoff, Anibal
Liguori, Nora Fernandez
Lazaro, Luciana
Menichini, Maria Laura
Miguez, Jimena
Orzuza, Gabriela
Palavecino, Alfredo
Pappolla, Agustin
Pigretti, Santiago
Pita, Cacilia
Ruiz, Emiliano
Silva, Berenice
Zentil, Guillermo
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 57
[33] Incidence of infections and severe lymphopenia in patients newly initiating cladribine tablets or fingolimod for treatment of multiple sclerosis: CLARION study
Hillert, J.
Butzkueven, H.
Soilu-Hanninen, M.
Ziemssen, T.
Kuhle, J.
Berger, J. R.
Aydemir, A.
Sonajalg, J.
Bezemer, I.
Sabido, M.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 639 - 640
[34] Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Alvarez-Gonzalez, Cesar
Adams, Ashok
Mathews, Joela
Turner, Benjamin P.
Giovannoni, Gavin
Baker, David
Schmierer, Klaus
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (07): : 506 - 511
[35] REBOUND THYMIC HYPERPLASIA AFTER TREATMENT OF CUSHINGS-SYNDROME
DOPPMAN, JL
OLDFIELD, EH
CHROUSOS, GP
NIEMAN, L
UDELSMAN, R
CUTLER, GB
LORIAUX, DL
AMERICAN JOURNAL OF ROENTGENOLOGY, 1986, 147 (06) : 1145 - 1147
[36] Fatal rebound of multiple sclerosis after fingolimod discontinuation: a neuropathological description
Vercellino, M.
Cavalla, P.
Capello, E.
Bandini, F.
Uccelli, A.
Giordana, M. T.
Mancardi, G. L.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 794 - 794
[37] FingolimodSevere rebound of multiple sclerosis after fingolimod withdrawal: case report
Reactions Weekly, 2020, 1785 (1) : 233 - 233
[38] Paroxysmal dysarthria-ataxia syndrome resolving after fingolimod treatment
Rossi, Silvia
Studer, Valeria
Motta, Caterina
Centonze, Diego
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 350 (1-2) : 101 - 102
[39] Rebound of Disease Activity after Fingolimod Discontinuation: Report of Six Cases
Siva, Aksel
Uygunoglu, Ugur
Tutuncu, Melih
Altintas, Ayse
Saip, Sabahattin
NEUROLOGY, 2016, 86
[40] Rebound of disease activity after fingolimod withdrawal: can we predict it?
Dotor Garcia-Soto, J.
Meca Lallana, V.
Quintas, S.
Aguirre, C.
Sanchez, P.
Vivancos, J.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 927 - 928

← 1 2 3 4 5 →